Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy

Download video

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy

282 views

VJHemOnc – Video Journal of Hematology & HemOnc

1 year ago

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy

6:53

Glofitamab for Richter’s Transformation

by CLL Society

16:37

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE

by SSBMT جمعية الخلايا الجذعية

$Advantages of bispecific antibodies for lymphoma: mosunetuzumab, epcoritamab \& glofitamab$

1:31

Advantages of bispecific antibodies for lymphoma: mosunetuzumab, epcoritamab \& glofitamab

by VJHemOnc – Video Journal of Hematology \& HemOnc

1:29

STARGLO 2-year follow-up: durability of responses in patients with DLBCL receiving Glofitamab-GemOx

by VJHemOnc – Video Journal of Hematology \& HemOnc

$An update of the NP30179 trial: a single-arm study assessing glofitamab in R\/R MCL$

1:24

An update of the NP30179 trial: a single-arm study assessing glofitamab in R\/R MCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

2:57

A Phase II study of glofitamab plus Pola-R-CHP for patients with high-risk DLBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

3:02

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma

by Global Resource for Advancing Cancer Education

2:54

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

1:22

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy

by VJHemOnc – Video Journal of Hematology \& HemOnc

3:27

High Haematocrit due to SGLT2i: Lets Bleep Haematology😃

by Haematology, Morphology, FRCPath Exams

6:23

Mantle Cell Lymphoma: Therapy for Relapsed Disease - 2025 Blood Cancer Video Library

by Global Resource for Advancing Cancer Education

$Management of Relapsed and Refractory Large B Cell Lymphoma-Latest BSH UK Guidelines$

8:17

Management of Relapsed and Refractory Large B Cell Lymphoma-Latest BSH UK Guidelines

by Haematology, Morphology, FRCPath Exams

4:22

Treatment Options of B-Cell Lymphoma: Glofitamab vs. Epcoritamab - Blood Cancer Video Library 2023

by Global Resource for Advancing Cancer Education

$The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R\/R DLBCL$

2:04

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R\/R DLBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Updates from the Phase II trials of glofitamab and epcoritamab for R\/R LBCL$

1:49

Updates from the Phase II trials of glofitamab and epcoritamab for R\/R LBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$The benefits of glofitamab in R\/R DLBCL post-CAR-T therapy$

1:15

The benefits of glofitamab in R\/R DLBCL post-CAR-T therapy

by VJHemOnc – Video Journal of Hematology \& HemOnc

1:26

Bispecifics in NHL: epcoritamab and glofitamab

by VJHemOnc – Video Journal of Hematology \& HemOnc

1:43

Preliminary results from NP40126: Glofitamab and R-CHOP in NHL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$CD20\/CD3 bispecific antibodies in R\/R DLBCL: glofitamab and epcoritamab$

1:21

CD20\/CD3 bispecific antibodies in R\/R DLBCL: glofitamab and epcoritamab

by VJHemOnc – Video Journal of Hematology \& HemOnc

$Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R\/R LBCL, including HGBCL$

2:02

Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R\/R LBCL, including HGBCL

by VJHemOnc – Video Journal of Hematology \& HemOnc

$COLUMVI (glofitamab-gxbm)- relapsed or refractory diffuse large B-cell lymphoma$

1:57

COLUMVI (glofitamab-gxbm)- relapsed or refractory diffuse large B-cell lymphoma

by Pharmacy Talk USA

8:12

Drs. Melody, Phillips discuss glofitamab trial, other MCL highlights at SOHO 2025

by The Society of Hematologic Oncology

$Relapsed and Refractory Diffuse Large B-Cell Lymphoma$

46:48

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

by Lymphoma Research Foundation

Best on Vidoe

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy